Kusne S, Tobin D, Pasculle A W, Van Thiel D H, Ho M, Starzl T E
Department of Surgery, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15260.
Transplantation. 1994 Feb;57(3):398-402. doi: 10.1097/00007890-199402150-00014.
Thirty randomly selected patients with advanced chronic liver disease, which had been evaluated for possible liver transplantation, were sampled endoscopically at 7 alimentary tract locations to assess the frequency and amount of Candida carriage. Eighty-one percent (127/156) of the samples obtained contained Candida and 53% (82/156) yielded high counts (> 300 CFU/ml). The most predominant Candida species isolated at each site was Candida albicans, which accounted for 103 (64%) of the 160 fungal isolates. The other Candida species isolated included C tropicalis 30 (19%), C krusei 16 (10%), and C glabrata 11 (7%). Although the number of sites at which yeast was present and the quantities of yeast at each site varied widely among the patients studied, 100% of the patients had Candida in at least one site of the gastrointestinal tract. Eighty-six percent (24/28) of the duodenal aspirates contained Candida and 50% (14/28) of the duodenal samples contained greater than 300 CFU/ml. A positive culture from the stomach was a reliable predictor of the presence of Candida in the duodenum (P = 0.0001), but a positive culture at no other site readily predicted the presence of Candida at yet another site. Importantly, there was no correlation between the presence or absence of Candida in either oral or rectal swabs and colonization at other anatomic sites within the gastrointestinal tract. These findings are important in liver transplantation, particularly in those cases in which the bowel has been opened to create a choledochojejunostomy anastomosis. The operative attempts to reduce gastrointestinal fungal carriage using oral antifungal agents may be justified before liver transplantation in an effort to lower the risk of posttransplantation fungal infections, particularly in those patients expected to have a Roux-en-Y choledochojejunostomy biliary reconstruction.
随机选取30例已接受肝移植可能性评估的晚期慢性肝病患者,在内镜下于7个消化道部位取样,以评估念珠菌携带的频率和数量。所取样本中81%(127/156)含有念珠菌,53%(82/156)念珠菌计数较高(>300 CFU/ml)。在每个部位分离出的最主要念珠菌种类是白色念珠菌,在160株真菌分离物中占103株(64%)。分离出的其他念珠菌种类包括热带念珠菌30株(19%)、克柔念珠菌16株(10%)和光滑念珠菌11株(7%)。尽管在所研究的患者中,念珠菌存在的部位数量以及每个部位的念珠菌数量差异很大,但100%的患者胃肠道至少有一个部位存在念珠菌。十二指肠抽吸物中86%(24/28)含有念珠菌,十二指肠样本中50%(14/28)念珠菌含量大于300 CFU/ml。胃培养阳性是十二指肠存在念珠菌的可靠预测指标(P = 0.0001),但其他部位培养阳性并不能轻易预测另一部位是否存在念珠菌。重要的是,口腔或直肠拭子中念珠菌的有无与胃肠道其他解剖部位的定植之间没有相关性。这些发现对肝移植很重要,特别是在那些为建立胆总管空肠吻合术而打开肠道的病例中。在肝移植前,使用口服抗真菌药物降低胃肠道真菌携带量的手术尝试可能是合理的,以降低移植后真菌感染的风险,特别是在那些预计要进行Roux-en-Y胆总管空肠吻合术式胆道重建的患者中。